ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO24

Community APOL1 Research Engagement (CARE)

Session Information

  • Informational Posters
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • No subcategory defined

Authors

  • Olabisi, Opeyemi A., Duke University School of Medicine, Durham, North Carolina, United States
  • Soldano, Karen, Duke University School of Medicine, Durham, North Carolina, United States
  • Smith, Maurice Walter, Duke University School of Medicine, Durham, North Carolina, United States
  • Barrett, Nadine J., Duke University School of Medicine, Durham, North Carolina, United States
  • Wolf, Myles, Duke University School of Medicine, Durham, North Carolina, United States
Description

Community APOL1 Research Engagement (CARE) is a registry of adults with APOL1-mediated kidney disease. African Americans are 4 times more likely to develop kidney failure as White Americans. Therefore, African Americans who represent 13% of the U.S. population account for >35% of patients with end stage kidney disease (ESKD). Carriage of two APOL1 risk alleles (high-risk genotype) is associated with increased incidence of chronic kidney disease (CKD) and its accelerated progression to ESKD. These APOL1 coding variants (G1 and G2) are found almost exclusively among individuals of recent West African ancestry and are believed to explain ~40% of the excess risk of ESKD among African Americans. However, APOL1 genotyping is not routinely performed as part of clinical care. Most African Americans with APOL1-mediated CKD are not aware of their disease. Moreover, Black Americans are perennially underrepresented in clinical trials—representing <5% of clinical trial participants.

The goal of CARE is to increase the awareness of APOL1-Mediated kidney disease in the African American community by providing accessible educational information and free screening for APOL1 genotype and for CKD. 5000 Black adults (age 18-70 years) will be screened. 600 Blacks with high-risk genotype, proteinuria (>300mg/day) and CKD (including FSGS and hypertension-associated kidney disease) will be enrolled into CARE registry. Research lab results will be reported to participants who desire to receive it.

For further information about CARE, please visit: https://kidneycareandjustice.com/

Funding

  • This study is funded by NIMHD; R01 MD016401-01
Abstract: INFO24

Community APOL1 Research Engagement (CARE)

Session Information

  • Informational Posters
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category:

  • No subcategory defined

Authors

  • Olabisi, Opeyemi A., Duke University School of Medicine, Durham, North Carolina, United States
  • Soldano, Karen, Duke University School of Medicine, Durham, North Carolina, United States
  • Smith, Maurice Walter, Duke University School of Medicine, Durham, North Carolina, United States
  • Barrett, Nadine J., Duke University School of Medicine, Durham, North Carolina, United States
  • Wolf, Myles, Duke University School of Medicine, Durham, North Carolina, United States
Description

Community APOL1 Research Engagement (CARE) is a registry of adults with APOL1-mediated kidney disease. African Americans are 4 times more likely to develop kidney failure as White Americans. Therefore, African Americans who represent 13% of the U.S. population account for >35% of patients with end stage kidney disease (ESKD). Carriage of two APOL1 risk alleles (high-risk genotype) is associated with increased incidence of chronic kidney disease (CKD) and its accelerated progression to ESKD. These APOL1 coding variants (G1 and G2) are found almost exclusively among individuals of recent West African ancestry and are believed to explain ~40% of the excess risk of ESKD among African Americans. However, APOL1 genotyping is not routinely performed as part of clinical care. Most African Americans with APOL1-mediated CKD are not aware of their disease. Moreover, Black Americans are perennially underrepresented in clinical trials—representing <5% of clinical trial participants.

The goal of CARE is to increase the awareness of APOL1-Mediated kidney disease in the African American community by providing accessible educational information and free screening for APOL1 genotype and for CKD. 5000 Black adults (age 18-70 years) will be screened. 600 Blacks with high-risk genotype, proteinuria (>300mg/day) and CKD (including FSGS and hypertension-associated kidney disease) will be enrolled into CARE registry. Research lab results will be reported to participants who desire to receive it.

For further information about CARE, please visit: https://kidneycareandjustice.com/

Abstract: INFO24

Community APOL1 Research Engagement (CARE)

Session Information

  • Informational Posters
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category:

  • No subcategory defined

Authors

  • Olabisi, Opeyemi A., Duke University School of Medicine, Durham, North Carolina, United States
  • Soldano, Karen, Duke University School of Medicine, Durham, North Carolina, United States
  • Smith, Maurice Walter, Duke University School of Medicine, Durham, North Carolina, United States
  • Barrett, Nadine J., Duke University School of Medicine, Durham, North Carolina, United States
  • Wolf, Myles, Duke University School of Medicine, Durham, North Carolina, United States
Description

Community APOL1 Research Engagement (CARE) is a registry of adults with APOL1-mediated kidney disease. African Americans are 4 times more likely to develop kidney failure as White Americans. Therefore, African Americans who represent 13% of the U.S. population account for >35% of patients with end stage kidney disease (ESKD). Carriage of two APOL1 risk alleles (high-risk genotype) is associated with increased incidence of chronic kidney disease (CKD) and its accelerated progression to ESKD. These APOL1 coding variants (G1 and G2) are found almost exclusively among individuals of recent West African ancestry and are believed to explain ~40% of the excess risk of ESKD among African Americans. However, APOL1 genotyping is not routinely performed as part of clinical care. Most African Americans with APOL1-mediated CKD are not aware of their disease. Moreover, Black Americans are perennially underrepresented in clinical trials—representing <5% of clinical trial participants.

The goal of CARE is to increase the awareness of APOL1-Mediated kidney disease in the African American community by providing accessible educational information and free screening for APOL1 genotype and for CKD. 5000 Black adults (age 18-70 years) will be screened. 600 Blacks with high-risk genotype, proteinuria (>300mg/day) and CKD (including FSGS and hypertension-associated kidney disease) will be enrolled into CARE registry. Research lab results will be reported to participants who desire to receive it.

For further information about CARE, please visit: https://kidneycareandjustice.com/